Major Scope
- Cardiovascular Case Reports
- Oncology Case Reports
- Surgical Case Reports
- Gastroenterological Case Reports
- Neurological Case Reports
- Dermatological Case Reports
- Respiratory Case Reports
- Obstetrics/Gynecology Case Reports
- Nephrology Case Reports
- Immunology Case Reports
- Paediatric Case Reports
- Orthopedics Case Reports
- Dental Case Reports
Abstract
Citation: Clin Case Rep Int. 2026;10(1):1770.DOI: 10.25107/2638-4558.1770
Single-Session Off-Label Administration of Poly-L-Lactic Acid Microspheres (Juläine™) Across Multiple Facial and Cervical Subunits: An Independent Case Report
Loghem JV, Kristof S and Kubik P*
UMA Academy, Amsterdam, The Netherlands
Sk Aesthetics, Jona, Switzerland
K-LAB Badania i Rozwój, 81-312 Gdynia, Poland
*Correspondance to: Paweł Kubik
PDF Full Text Research Article | Open Access
Abstract:
Background: Injectable Poly-L-Lactic Acid (PLLA) is a collagen biostimulator used in aesthetic medicine. PLLA-LASYNPRO™ (Juläine™, Nordberg Medical AB, Stockholm, Sweden), a spherical-microsphere formulation of PLLA, holds CE-mark approval restricted to correction of shallow to deep nasolabial folds. The safety and clinical outcome of extended-area application of this formulation have not been reported. Objective: To describe the tolerability and qualitative clinical observations following single-session administration of PLLA-LASYNPRO™ across multiple facial and cervical subunits including higher-risk regions (forehead, temples, infraorbital, perioral, neck) in an adult patient with age-related loss of skin firmness, hydration and surface evenness. Methods: One patient received a single session. Five vials of Juläine™ (150 mg PLLA each) were each reconstituted in 5 mL bacteriostatic saline and delivered via 25G blunt-tip cannulae (38 mm/50 mm) with area-specific techniques. Outcome was assessed by standardized photography and clinical review at baseline and 14 weeks. Results: Qualitative visual assessment by the treating investigators suggested changes in skin texture and firmness and overall facial and cervical skin quality 14 weeks after the treatment. Adverse events were limited to transient oedema (3 days) and tenderness (2 days); no erythema, nodules, granulomas or vascular events occurred. Conclusion: Single-session delivery of PLLA-LASYNPRO™ across multiple on-label and off-label facial and cervical areas was well tolerated and produced a clinically perceptible 14-week improvement. The procedure was performed by highly experienced clinicians and should not be uncritically replicated. Findings warrant confirmation in structured prospective studies.
Keywords:
Regeneration; Skin quality; Poly-L-lactic acid; PLLA; Biostimulator; Forehead; Periocular; Perioral; Neck; Off-label
Cite the Article:
Loghem JV, Kristof S, Kubik P. Single- Session Off-Label Administration of Poly-L-Lactic Acid Microspheres (Juläine™) Across Multiple Facial and Cervical Subunits: An Independent Case Report. Clin Case Rep Int. 2026; 10: 1770..
Journal Basic Info
- Impact Factor: 4.082**
- H-Index: 6
- ISSN: 2638-4558
- DOI: 10.25107/2638-4558